Company: BDRX
Filing Date: 2025-01-28
Form Type: 424B3
Source: 0001214659-25-001409
Chunk: 22

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-28
Form: 424B3
Chunk 22
---
 sale of                                                                   
 the Commitment Shares if issued to the Selling Shareholder to release the Company of its liability to pay the Commitment Fee. We may receive                                                      
 up to $35.0 million in gross proceeds from C/M in connection with the sale of our Depositary Shares under the Purchase Agreement. We intend                                                       
 to use any net proceeds from any sales of Depositary Shares to C/M under the Equity Financing to fund our development programs, for working                                                       
 capital and other general corporate purposes. Pending other uses, we intend to invest the net proceeds to us in short-term, interest-bearing                                                      
 investments. We cannot predict whether the net proceeds invested will yield a favorable return. See “Use of Proceeds.”                                                                            |

| 11 |

| Risk factors    |     | You should read the “Risk Factors” section starting on page 13 of this prospectus for a discussion of factors to consider before deciding to invest in our securities.                       |
| Dividend policy |     | We have never declared or paid any cash dividends to our shareholders, and we currently do not expect to declare or pay any cash dividends in the foreseeable future. See “Dividend Policy.” |
| Listing         |     | Our Depositary Shares are listed on the NASDAQ Capital Market under the symbol “BDRX.”                                                                                                       |

| 12 |

<div align='center'>RISK FACTORS</div>

Our business has significant risks. In addition to the other information included in this annual report, including the matters addressed in the section of the annual report entitled “Cautionary Note Regarding Forward-Looking Statements” and in our financial statements and the related notes, you should consider carefully the risks described below. The risks and uncertainties described below are not the only risks and uncertainties we may face. Additional risks and uncertainties not presently known to us, or that we currently consider immaterial could also negatively affect our business, financial condition, results of operations, prospects, profits and stock prices. If any of the risks described below actually occur, our business, financial condition, results of operations, prospects, profits and stock prices could be materially adversely affected.

Summary of Risk Factors

The occurrence of one or more of the events or circumstances described in this section titled “ Risk Factors,” alone or in combination with other events or circumstances, may materially adversely affect our business, financial condition and operating results. In that event, the trading price of our securities could decline, and you could lose all or part of your investment. Such risks include, but are not limited